ArticleMedicine2025
Clinical features and prognostic factors of salivary adenoid cystic and mucoepidermoid carcinomas.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PRAME promotes invasion and metastasis of salivary adenoid cystic carcinoma by regulating RARα stability via the cullin2 ubiquitin-proteasome system.Clinical and translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenoid cystic carcinoma (ACC) and mucoepidermoid carcinoma (MEC) are common malignant tumors of the salivary glands. This study aimed to compare ACC and MEC regarding clinical features and survival factors. Data from all ACC and MEC cases between 2000 and 2020 were extracted from the US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. Clinical features, overall survival (OS), and disease-specific survival (DSS) were assessed for both cancer types. The study included 1426 ACC cases and 3190 MEC cases. In ACC, 580 patients (40.7%) were male, while in MEC, 1494 patients (46.8%) were male. The mean OS was significantly higher for MEC than for ACC (79.33 ± 58.62 months vs 73.44 ± 57.18 months, P < .001), and the mean DSS was greater for MEC (46.80 ± 39.26 months vs 29.06 ± 29.79 months, P < .001). Independent predictors of worse OS and DSS in ACC included age ≥ 60 years, male gender, submandibular gland involvement, advanced stage, lymph node involvement, distant metastasis, and surgical treatment (all P < .05). This study found that MEC has a significantly better prognosis than ACC, with several common factors linked to worse outcomes for both types, including age ≥60 years and male gender, while surgery acted as a significant protective factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.